Immunosuppressants I Flashcards Preview

Board Review - B - Systems Pharmacology > Immunosuppressants I > Flashcards

Flashcards in Immunosuppressants I Deck (40)
1

cyclosporine MOA

inhibitor of calcineurin
binds cyclophilin

block T cell activation - prevent IL-2 transcription

2

adverse cyclosporine

nephrotoxic

gingival hyperplasia
hirsutism

3

tacrolimus MOA

aka - FK506

inhibitor of calcineurin
bind FKBP

block T cell activation - prevent IL-2 transcription

4

tacrolimus adverse

nephrotixic

diabetes and neurotoxicity

5

sirolimus

aka rapamycin

inhibitor of mTOR
bind FKBP

block T cell activation and B cell activation

prevent response to IL-2

6

adverse sirolimus

not nephrotoxic

anemia, thrombocytopenia, leukopenia, insulin resistance, hyperlipidemia

7

daclizumab

mAb - block IL-2R

8

basiliximab

mAb - block IL-2R

9

axathioprine

precursor - 6-MP

inhibit lymphocyte proliferation - inhibit nucleotide synthesis

10

azathioprine adverse

degraded xanthine oxidase

more toxic with allopurinol

11

glucocorticoids

inhibit NF-KB

suppress T and B cell function
-decreased transcription of cytokines

12

adverse glucocorticoids

cushing syndrome

13

tx of transplant rejection

cyclosporine
tacrolimus
sirolimus
daclizumab
basiliximab
azathioprine
glucocorticoids

14

aldesleukin

recombinant IL-2

tx - renal cell carcinoma
metastatic melanoma

15

epoetin alfa

recombinant EPO

tx anemias

16

filgrastim

recombinant G-CSF

recovery of bone marrow

17

sargramostim

recombinant - GM-CSF

recovery of bone marrow

18

IFN-a recombinant

tx chronic hep B and C
kaposi sarcoma
malignant melanoma

19

IFN-B recombinant

tx MS

20

IFN-gamma recombinant

tx chronic granulomatous disease

21

romoplostim

recombinant cytokine

for thrombocytopenia

22

oprelvekin

recombinant IL-11

tx thromboctopenia

23

alemtuzumab

CD52

tx CLL

24

bebacizumab

VEGF

25

cetuximab

EFGR

stage IV colorectal cancer

26

rituximab

CD20

B-cell non hodgkin lmyphoma
CLL
RA
ITP

27

trastuzumab

HER2/neu

breast cancer

28

adalimumab

soluble TNF-a

29

etanercept

decoy TNF-a receptor

30

infliximab

soluble TNF-a

31

eculizumab

complement C5

tx - paroxysmal nocturnal hemoglobinuria

32

natalizumab

a4 - integrin

MS
crohn disease

33

risk of PML pt with JC virus

natalizumab - a4 integrin - WBC adhesion

34

abciximab

platelet IIb/IIIa

2 x 3 = six = ab six imab

antiplatelet - prevent ischemic complications during percutaneous coronary intervention

35

denosumab

RANK-L

osteoporosis tx
-inhibit osteoclast activity

denOSumab

36

digoxin immune Fab

digoxin - antidote toxicity

37

omalizumab

IgE

allergic asthma
-revent IgE binding Fc E RI

38

palivizumab

RSV F protein

RSV prophylaxis - high risk infant

39

ranibizumab

VEGF

tx neovascular macular degeneration

40

bebacizumab

VEGF